IgG4-RD

Data from Trial Evaluating Eculizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder to be Presented at AAN Annual Meeting

Alexion Pharmaceuticals, Inc, announced that nine abstracts have been accepted for presentation at the 72nd annual meeting of the American Academy of Neurology (AAN) in Toronto, Ontario, Canada from April 25 through May 1, 2020. Long-term safety and efficacy results from the Phase 3 PREVENT study and open-label extension of SOLIRIS® (eculizumab)...